筛查与进展为湿性年龄相关性黄斑变性相关的药物
本研究采用嵌套病例对照设计,基于行政保险索赔数据,应用树状扫描方法同时评估约4000种仿制药及药物类别与新生血管性AMD(nAMD)进展的关联。在P≤0.01且相对风险≥2.0的阈值下,检测到19种药物暴露与病例组暴露频率低于对照组相关,包括已有因果证据的药物(如甲地孕酮)、无既往证据但值得进一步探索的药物(如多奈哌齐、阿法依泊汀)等。结论认为该探索性药物筛查研究为后续研究识别了若干潜在靶点。
要点
- 在约4000种药物中检测到19种与nAMD进展风险降低相关。
- 甲地孕酮已有因果证据,多奈哌齐和阿法依泊汀无既往证据但值得探索。
- 研究为探索性,结果需后续研究验证。
核心结论
- 该探索性药物筛查研究识别了若干与延迟进展至nAMD相关的药物,为后续研究提供了潜在靶点。
研究设计与样本
- 采用嵌套病例对照研究设计,病例为nAMD患者,对照按年龄、性别和近期医疗使用1:4可变比例风险集匹配。
- 使用树状扫描方法评估药物暴露与nAMD进展的关联,数据来自新泽西和宾夕法尼亚州Medicare数据及IBM MarketScan国家数据库。
主要发现
- 在约4000种仿制药和药物类别中,检测到19种不同药物暴露具有统计学显著的大相对风险,表明病例组暴露频率低于对照组。
- 检测到的药物包括:已有因果证据的药物(如甲地孕酮);无既往证据但值得进一步探索的药物(如多奈哌齐、阿法依泊汀);有替代生物学解释的药物(如司维拉姆);以及可能因与其他警示药物相关而出现统计警示的药物。
关键数值与推荐
- 统计警示的先验阈值设定为P≤0.01。
- 关注大效应量关联,相对风险≥2.0。
临床怎么用
- 这些发现尚属探索性,不应直接改变临床用药以预防或延迟nAMD进展。
- 识别出的药物可作为未来研究靶点,进一步评估其预防或延迟进展至晚期AMD的潜力。
局限性
- 本研究为探索性药物筛查研究,结果需后续研究进一步评估和确定。
- 部分统计警示可能源于药物与其他警示药物的相关性,而非直接生物学效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is an urgent need for treatments that prevent or delay development to advanced age-related macular degeneration (AMD). Drugs already on the market for other conditions could affect progression to neovascular AMD (nAMD). If identified, these drugs could provide insights for drug development targets. The objective of this study was to use a novel data mining method that can simultaneously evaluate thousands of correlated hypotheses, while adjusting for multiple testing, to screen for associations between drugs and delayed progression to nAMD. DESIGN: We applied a nested case-control study to administrative insurance claims data to identify cases with nAMD and risk-set sampled controls that were 1:4 variable ratio matched on age, gender, and recent healthcare use. PARTICIPANTS: The study population included cases with nAMD and risk set matched controls. METHODS: We used a tree-based scanning method to evaluate associations between hierarchical classifications of drugs that patients were exposed to within 6 months, 7 to 24 months, or ever before their index date. The index date was the date of first nAMD diagnosis in cases. Risk-set sampled controls were assigned the same index date as the case to which they were matched. The study was implemented using Medicare data from New Jersey and Pennsylvania, and national data from IBM MarketScan Research Database. We set an a priori threshold for statistical alerting at P ≤ 0.01 and focused on associations with large magnitude (relative risks ≥ 2.0). MAIN OUTCOME MEASURES: Progression to nAMD. RESULTS: Of approximately 4000 generic drugs and drug classes evaluated, the method detected 19 distinct drug exposures with statistically significant, large relative risks indicating that cases were less frequently exposed than controls. These included (1) drugs with prior evidence for a causal relationship (e.g., megestrol); (2) drugs without prior evidence for a causal relationship, but potentially worth further exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative biologic explanations for the association (e.g., sevelamer); and (4) drugs that may have resulted in statistical alerts due to their correlation with drugs that alerted for other reasons. CONCLUSIONS: This exploratory drug-screening study identified several potential targets for follow-up studies to further evaluate and determine if they may prevent or delay progression to advanced AMD.
引用
- Wang SV, Kulldorff M, Poor S, et al. Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 32777229. doi:10.1016/j.ophtha.2020.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。